Archive | Hot Mandates RSS feed for this section

Hot Life Science Investor Mandate 2: CMO / Corporate VC Doubles as Seed, Venture Investor

13 Nov

A medical device incubator and contract manufacturing organization (CMO) that also provides seed and venture funding to medical device companies is headquartered in the Western US. Typically, they provide up to $7 million in equity capital into companies. They are willing to consider companies globally. The firm currently has no set number of planned allocations, but they are willing to invest in as many companies as their facilities can handle.

The incubator is looking for companies that are in the medical device space. Within the medical device space, the firm is currently interested in companies developing disposable devices, reusable instruments, and surgical devices, among other relatively low-tech devices. The firm also is very interested in indications of cardiovascular, perivascular, orthopedics and diseases of the nervous system. The firm is willing to work with companies that are still developing their prototype to those that are into clinical trials. The firm prefers that a company’s product be eligible for the 510K regulatory pathway – as well as being eligible for reimbursement.

This organization is willing to work with companies that have incomplete management teams to those that have established corporate leadership. The firm almost exclusively deals with companies that are pre-revenue. The firm is willing to participate in the formation of a new company to the takeover of a more established one, and looks to leverage the firm’s capabilities in areas of R&D, Marketing, Sales and Prototyping in order to expedite the process of getting the companies device on the market.

Tags: , , ,

Hot Life Science Investor Mandate 3: Institutional Alternative Investor Seeks Companies At, Near Commercialization

13 Nov

An institutional alternative investment firm based in the Eastern US manages over $1 billion in total assets, and is currently making investments out of its second private equity fund. The firm looks to invest between $2 and $6 million into companies in exchange for an equity position preferably in the range of 10%-30%. The firm prefers to lead investments, but will co-invest with other accredited and established investment firms. The firm typically allocates to 3-4 firms in a given year and perfers companies located within the US.

The firm is currently interested in high-growth companies in the Medical Devices, Healthcare IT and R&D services sectors that have begun or are very near the commercialization stage. The firm is highly opportunistic in terms of subsector and indication in these areas, although companies that they have been involved with in the past include companies developing surgical tools, diagnostics devices, clinical trial analysis software, and companies developing platforms for identifying and screening potential therapeutic compounds.

This particular organization prefers to invest in companies with complete management teams that are currently earning approximately $1 million in annual revenue. That being said, the firm will also consider exceptional opportunities in companies that are pre-revenue on a case by case basis. The firm looks to be an active investor in selected companies seeking a board seat and often participating in follow on rounds on financing when required.

Tags: ,

Hot Life Science Investor Mandate 1: CRO’s Corporate Venture Arm Leverages Services for Equity

6 Nov

The corporate venture capital arm of a global contract research organization (CRO) has the ability to allocate anywhere from $100,000 to $2 million of equity capital to companies. However, the arm only invests in opportunities where it can leverage its CRO services as a piece of the investment, and as such, looks to tailor its CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities worldwide, and plans to be involved with 6-10 companies over the next 6-9 months.

The corporate VC is willing to consider making investments into companies developing medical devices, diagnostics, and therapeutics that are able to utilize their parent company’s CRO services to advance their product into or through clinical trials. Currently, they are most interested in companies developing therapeutics and biologics with a lead asset anywhere from 6-9 months pre-IND, to Phase III of clinical trials. The arm is completely opportunistic in terms of subsector and indication, and is willing to consider companies targeting orphan indications.

The corporate VC often acts as a co-investor, and generally does not require a board seat. Despite not being active on the board, the firm is a long-term investor and looks to provide market, development, and regulatory insight and strategic advice into selected companies.

Tags: , ,

Hot Life Science Investor Mandate 2: US-based PE Invests Widely Across Healthcare Space

6 Nov

A private equity group based in the Central US has committed $150 million of capital, and typically invests in companies with EBITDA of $2-15 million; investments are generally acquisitions, and may consist of up to $20 million equity with the potential for leveraged investments of up to $75 million. The firm invests in the USA and Canada, and may consider investing in other countries on a case-by-case basis.

Healthcare is a focus industry for the group, and they invest widely across the sector. As the firm prefers to invest in companies that are cash-flow positive, investments are generally in companies that have products on the market. The PE group considers investments in any indication (including rare diseases).

The group prefers to invest in family companies or other companies that have a small number of shareholders. The firm looks for strong management teams, but has no fixed industry or academic criteria for assessing managers. Thus far, they have only invested in privately held companies, but the firm may consider investments in public companies.

Tags: , , ,

Hot Life Science Investor Mandate 3: Opportunistic European VC Actively Seeking New Investments

6 Nov

A venture capital firm with several offices worldwide is based primarily in Europe, and co-manages an early-stage fund focused on academic spinouts and seed investments in Europe. The firm has approximately €500M AUM, and is currently managing four active funds. The firm makes equity investments in life science and biomedical technology companies at all stages of development. However, the VC prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €3M to €7M. The firm looks for companies that are based in the US, Canada, and Europe. They are actively screening new investment opportunities.

This group is fairly opportunistic in the life sciences space, but generally targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and has no specific preference in indication. In medical devices, they have a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The VC invests in companies at all stages of their development. For drug development, they invest from late preclinical to mid-stage clinical development. Sometimes they will consider companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

Tags: , , ,

Hot Life Science Investor Mandate 1: Family Office to Make Several Investments in Coming Months

31 Oct

A family office based in the Eastern US manages 4 funds for a total of approximately $400 million in assets under management. They are currently investing out of their 4th fund, which has $100 million focused exclusively on the life sciences. The office looks to provide up to $5 million of preferred equity capital in the initial investment round, and up to $10 million over the life of the investment. They are very flexible in terms of period to exit, but generally look to exit in around 5 years. They plan to make 2-3 investments over the next 6-9 months and will consider companies globally.

The family office is currently looking for companies developing Therapeutics, Diagnostics and Medical Technology. Within therapeutics, which is their primary focus, companies with an asset in Phase II are currently of most interest. However, they will consider companies with assets as early as 2 years away from human trial data. Within diagnostics, they generally require that the diagnostic be at the commercial stage or have significant positive clinical data. For medical technology they require that the device have some in-human data before being considered for investment. Also, the firm is not interested in medtech companies developing devices that are incrementally improved versions of devices already on the market, groundbreaking technologies and platforms are the firms focus in this area.

Tags: , ,

Hot Life Science Investor Mandate 2: Virtual Pharma Could Acquire Three Companies Within a Year

31 Oct

A virtual pharmaceutical development company based in the Western US is looking to in-license pharmaceutical assets and bring them through clinical proof of concept, and then sell them to large pharmaceutical companies. The firm is looking for candidates that require less than 3.5 years and $15 million to human proof of concept. They also look to invest in assets – not companies – and as such, they are able to consider assets developed by companies anywhere in the world. The firm is currently positioned to acquire up to 3 assets in the next 6-9 months.

The company is looking to in-license both small and large molecules in either the pre-clinical stage or Phase I of clinical development. For assets in the pre-clinical stage, the firm is not interested in lead optimization projects, and requires that the asset be within at least 12-18 months of entering Phase I. The firm’s current pipeline includes therapeutics targeting the indications of Dermatology, Type 2 Diabetes, Pulmonary Disorders.

The company looks to take a majority equity stake in its chosen assets, leaving the remainder of equity in the hands of the originator.

Tags:

← Older Entries
Newer Entries →